Accession | Title | Sample type | Organism(s) | Ch | Platform | Series | Supplementary | Contact | Release date |
---|---|---|---|---|---|---|---|---|---|
Filter | GSE165052 | ||||||||
GSM4988749 |
P2A1: Sensitive PH039 third passage source tumor
|
SRA | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM4988750 |
P2A2: Sensitive PH039 third passage source tumor
|
SRA | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM4988751 |
P2A3: Sensitive PH039 third passage source tumor
|
SRA | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM4988752 |
F1A3: Sensitive PH039 first passage niraparib treated tumor
|
SRA | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM4988753 |
F1A4: Sensitive PH039 first passage niraparib treated tumor
|
SRA | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM4988754 |
F1A5: Mixed phenotype PH039 first passage niraparib treated tumor
|
SRA | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM4988755 |
F251: Mixed phenotype PH039 first passage niraparib treated tumor
|
SRA | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM4988756 |
F351: Resistant PH039 second passage niraparib treated tumor
|
SRA | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM4988757 |
F352: Resistant PH039 second passage niraparib treated tumor
|
SRA | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM4988758 |
F451: Resistant PH039 third passage niraparib treated tumor
|
SRA | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM4988759 |
F452: Resistant PH039 third passage niraparib treated tumor
|
SRA | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM4988760 |
F453: Resistant PH039 third passage niraparib treated tumor
|
SRA | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM5025301 |
S0.1: Sensitive PH039 source tumor (array)
|
genomic | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM5025302 |
S0.2: Sensitive PH039 source tumor (array)
|
genomic | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM5025303 |
S2.1: Sensitive PH039 second passage source tumor (array)
|
genomic | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM5025304 |
S2.3-rep1: Sensitive PH039 second passage source tumor (array)
|
genomic | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM5025305 |
C1.2: Sensitive PH039 first passage niraparib treated tumor (array)
|
genomic | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM5025306 |
C2.1: PH039 second passage niraparib treated tumor (array)
|
genomic | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM5025307 |
C2.2: PH039 second passage niraparib treated tumor (array)
|
genomic | 1 |
|
Hu Li | Jun 16, 2021 | |||
GSM5025308 |
C3.1: Resistant PH039 third passage niraparib treated tumor (array)
|
genomic | 1 |
|
Hu Li | Jun 16, 2021 |